All Things Investigations – Navigating Secondary Tariffs with Mike Huneke and Brent Carlson
FCPA Compliance Report: The Impact of Secondary Tariffs on Global Trade with Mike Huneke and Brent Carlson
10 For 10: Top Compliance Stories For the Week Ending June 14, 2025
Daily Compliance News: June 9, 2025, The Repugnant Edition
Compliance in the Former Soviet Central Asian Republics
Episode 330 – Halyna Senyk on Anti-Corruption Progress in Ukraine
FINCast Ep. 39 – State of Russia Sanctions Two Years After the Invasion
Season 2 Episode 4 - Russia Enforcement and the involvement of DOJ's Task Force KleptoCapture
The Justice Insiders Podcast: The Latest on Russia Sanctions and the Enhanced Enforcement Environment
Episode 271 -- Deep Dive into Microsoft's OFAC Settlement for $3 Million
The New Cold War: Risk, Sanctions, Compliance Episode 27: “The Yukos Case: 20 Years Later”
The New Cold War: Risk, Sanctions, Compliance Episode 26: “International Sports: Politics, Corruption, Doping and Compliance”
The New Cold War: Risk, Sanctions, Compliance Episode 25: “Can the U.S. Seize the Russian Central Bank’s Assets?”
The New Cold War: Risk, Sanctions, Compliance Episode 23: "Former FBI Acting Director Andrew McCabe”
The New Cold War: Risk, Sanctions, Compliance Episode 20: "Rich Russians: From Oligarchs to Bourgeoisie"
The New Cold War: Risk, Sanctions, Compliance Episode 19: “Psychological Profiling, Crisis Management, and the New Cold War”
Compliance in Ukraine
FINCast Ep. 34 - A Storied Journey in the World of Financial Integrity: A Conversation with Stuart Levey
Putin's Oil Heist - Episode 5: Fighting From Afar
FCPA Compliance Report - Josh Fitzhugh on Trade Compliance Since the Russian Invasion of Ukraine
Russia’s full-scale invasion of Ukraine is now in its third year, and we continue to see unprecedented levels of activity and instability with public clashes between world leaders, trade wars, and critical foreign aid cuts by...more
Drugmaker AstraZeneca agreed on Saturday to buy biopharma company Alexion for $39 billion in cash and stock. In the deal—the “biggest by a health care company this year”—will help AstraZeneca expand into the immunology...more